Literature DB >> 11584870

Pharmacologic approaches to the management of alcoholism.

R F Anton1.   

Abstract

Our understanding of alcohol craving, both as a cause for chronic abuse and relapse and as a target for intervention, has been refined significantly in recent years. For example, craving experienced during alcohol withdrawal may be mediated by gamma-aminobutyric acid (GABA) and glutamate receptor mechanisms, whereas the memory of the rewarding aspects of alcohol may be mediated by dopamine, opiate, and glutamate systems. Therefore, pharmacologic treatments for alcohol dependence may be targeted to numerous pathways. This article will discuss animal and clinical studies of the opioid antagonists (primarily naltrexone), acamprosate, and disulfiram. The side effects and treatment recommendations for each drug will also be reviewed.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11584870

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  16 in total

Review 1.  Suicide in alcohol-dependent individuals: epidemiology and management.

Authors:  Sami P Pirkola; Kirsi Suominen; Erkki T Isometsä
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

2.  Disulfiram Use in an Elderly Man With Alcoholism and Heart Disease: A Discussion.

Authors:  Jeff C. Huffman; Theodore A. Stern
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2003-02

3.  The adoption of medications in substance abuse treatment: associations with organizational characteristics and technology clusters.

Authors:  Hannah K Knudsen; Lori J Ducharme; Paul M Roman
Journal:  Drug Alcohol Depend       Date:  2006-09-12       Impact factor: 4.492

Review 4.  The cannabinoid CB1 receptor antagonist, rimonabant, as a promising pharmacotherapy for alcohol dependence: preclinical evidence.

Authors:  Giancarlo Colombo; Alessandro Orrù; Paola Lai; Claudia Cabras; Paola Maccioni; Marina Rubio; Gian Luigi Gessa; Mauro A M Carai
Journal:  Mol Neurobiol       Date:  2007-07-03       Impact factor: 5.590

Review 5.  Pathological gambling: an update on neuropathophysiology and pharmacotherapy.

Authors:  Iulian Iancu; Katherine Lowengrub; Yael Dembinsky; Moshe Kotler; Pinhas N Dannon
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

6.  Preclinical evaluation of riluzole: assessments of ethanol self-administration and ethanol withdrawal symptoms.

Authors:  Joyce Besheer; Veronique Lepoutre; Clyde W Hodge
Journal:  Alcohol Clin Exp Res       Date:  2009-08       Impact factor: 3.455

7.  Pathological gambling: a review of phenomenological models and treatment modalities for an underrecognized psychiatric disorder.

Authors:  Pinhas N Dannon; Katherine Lowengrub; Yehudit Gonopolski; Ernest Musin; Moshe Kotler
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2006

8.  Comparison of naltrexone, 6alpha-naltrexol, and 6beta-naltrexol in morphine-dependent and in nondependent rhesus monkeys.

Authors:  Jun-Xu Li; Lance R McMahon; Charles P France
Journal:  Psychopharmacology (Berl)       Date:  2007-09-16       Impact factor: 4.530

9.  Substance Use Disorders and Neurologic Illness.

Authors:  Robert D. Davies; Christian Thurstone; Kelly Woyewodzic
Journal:  Curr Treat Options Neurol       Date:  2004-09       Impact factor: 3.598

Review 10.  Update on neuropharmacological treatments for alcoholism: scientific basis and clinical findings.

Authors:  Bankole A Johnson
Journal:  Biochem Pharmacol       Date:  2007-08-09       Impact factor: 5.858

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.